Glomerular nodular lesions, known as Kimmelstiel-Wilson nodules, are a pathological hallmark of progressive human diabetic nephropathy. We have induced severe diabetes in pigs carrying a dominant-negative mutant hepatocyte nuclear factor 1-alpha (HNF1α) P291fsinsC, a maturity-onset diabetes of the young type-3 (MODY3) gene in humans. In this model, glomerular pathology revealed that formation of diffuse glomerular nodules commenced as young as 1 month of age and increased in size and incidence until the age of 10 months, the end of the study period. Immunohistochemistry showed that the nodules consisted of various collagen types (I, III, IV, V and VI) with advanced glycation end-product (AGE) and Nε-carboxymethyl-lysine (CML) deposition, similar to those in human diabetic nodules, except for collagen type I. Transforming growth factor-beta (TGF-β) was also expressed exclusively in the nodules. The ultrastructure of the nodules comprised predominant interstitial-type collagen deposition arising from the mesangial matrices. Curiously, these nodules were found predominantly in the deep cortex. However, diabetic pigs failed to show any of the features characteristic of human diabetic nephropathy; e.g., proteinuria, glomerular basement membrane thickening, exudative lesions, mesangiolysis, tubular atrophy, interstitial fibrosis, and vascular hyalinosis. The pigs showed only Armanni-Ebstein lesions, a characteristic tubular manifestation in human diabetes. RT-PCR analysis showed that glomeruli in wild-type pigs did not express endogenous HNF1α and HNF1β, indicating that mutant HNF1α did not directly contribute to glomerular nodular formation in diabetic pigs. In conclusion, pigs harboring the dominant-negative mutant human MODY3 gene showed reproducible and distinct glomerular nodules, possibly due to AGE- and CML-based collagen accumulation. Although the pathology differed in several respects from that of human glomerular nodular lesions, the somewhat acute and constitutive formation of nodules in this mammalian model might provide information facilitating identification of the principal mechanism underlying diabetic nodular sclerosis.
References
[1]
Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, et al. (2012) An overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial 16: 483–521. doi: 10.1111/1744-9987.12147
[2]
White SL, Chadban SJ, Jan S, Chapman JR, Cass A (2008) How can we achieve equity in provision of renal replacement therapy? Bull World Health Organ 86: 229–237. doi: 10.2471/blt.07.041715
[3]
Kimmelstiel P, Wilson C (1936) Intercapillary Lesions in the Glomeruli of the Kidney. Am J Pathol 12: 83–98.7.
[4]
Hong D, Zheng T, Jia-qing S, Jian W, Zhi-hong L, et al. (2007) Nodular glomerular lesion: a later stage of diabetic nephropathy? Diabetes Res Clin Pract 78: 189–195. doi: 10.1016/j.diabres.2007.03.024
[5]
Heaf JG, L？kkegaard H, Larsen S (2001) The relative prognosis of nodular and diffuse diabetic nephropathy. Scand J Urol Nephrol 35: 233–238. doi: 10.1080/003655901750292024
[6]
Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, et al. (2009) Mouse models of diabetic nephropathy. J Am Soc Nephrol 20: 2503–2512. doi: 10.1681/asn.2009070721
[7]
Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, et al. (2006) Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 17: 2664–2669. doi: 10.1681/asn.2006070798
[8]
Inagi R, Yamamoto Y, Nangaku M, Usuda N, Okamoto H, et al. (2006) A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes 55: 356–366. doi: 10.2337/diabetes.55.02.06.db05-0702
[9]
Furuichi K, Hisada Y, Shimizu M, Okumura T, Kitagawa K, et al. (2011) Matrix metalloproteinase-2 (MMP-2) and membrane-type 1 MMP (MT1-MMP) affect the remodeling of glomerulosclerosis in diabetic OLETF rats. Nephrol Dial Transplant 26: 3124–3131. doi: 10.1093/ndt/gfr125
[10]
Hudkins KL, Pichaiwong W, Wietecha T, Kowalewska J, Banas M, et al. (2010) BTBR ob/ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol 21: 1533–1542. doi: 10.1681/asn.2009121290
[11]
Larsen MO, Wilken M, Gotfredsen CF, Carr RD, Svendsen O, et al. (2002) Mild streptozotocin diabetes in the G？ttingen minipig. A novel model of moderate insulin deficiency and diabetes. Am J Physiol Endocrinol Metab 282: E1342–1351.
[12]
Bellinger DA, Merricks EP, Nichols TC (2006) Swine models of type 2 diabetes mellitus: insulin resistance, glucose tolerance, and cardiovascular complications. ILAR J 47: 243–258. doi: 10.1093/ilar.47.3.243
[13]
Renner S, Braun-Reichhart C, Blutke A, Herbach N, Emrich D, et al. (2013) Permanent neonatal diabetes in INS(C94Y) transgenic pigs. Diabetes 62: 1505–1511. doi: 10.2337/db12-1065
[14]
Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, et al. (1996) Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature 384: 455–458. doi: 10.1038/384455a0
[15]
Yamagata K (2003) Regulation of pancreatic β-cell function by the HNF transcription network: lessons from maturity-onset diabetes of the young (MODY). Endocr J 50: 491–499. doi: 10.1507/endocrj.50.491
[16]
Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, et al. (1996) Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84: 575–585. doi: 10.1016/s0092-8674(00)81033-8
[17]
Pontoglio M (2000) Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J Am Soc Nephrol 11: S140–S143.
[18]
Umeyama K, Watanabe M, Saito H, Kurome M, Tohi S, et al. (2009) Dominant-negative mutant hepatocyte nuclear factor 1alpha induces diabetes in transgenic-cloned pigs. Transgenic Res 18: 697–706. doi: 10.1007/s11248-009-9262-3
[19]
Umeyama K, Honda K, Matsunari H, Nakano K, Hidaka T, et al. (2013) Production of diabetic offspring using cryopreserved epididymal sperm by in vitro fertilization and intrafallopian insemination techniques in transgenic pigs. J Reprod Dev 59: 599–603. doi: 10.1262/jrd.2013-069
[20]
Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, et al. (2000) Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11: 1656–1666.
[21]
Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, et al. (1997) Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 100: 2995–3004. doi: 10.1172/jci119853
[22]
Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA (1993) Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 90: 1814–1818. doi: 10.1073/pnas.90.5.1814
[23]
Ritchie S, Waugh D (1957) The pathology of Armanni-Ebstein diabetic nephropathy. Am J Pathol 33: 1035–1057.
[24]
Nerlich A, Schleicher E (1991) Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol 139: 889–899.
[25]
Makino H, Shikata K, Wieslander J, Wada J, Kashihara N, et al. (1994) Localization of fibril/microfibril and basement membrane collagens in diabetic glomerulosclerosis in type 2 diabetes. Diabet Med 11: 304–311. doi: 10.1111/j.1464-5491.1994.tb00276.x
[26]
Glick AD, Jacobson HR, Haralson MA (1992) Mesangial deposition of type I collagen in human glomerulosclerosis. Hum Pathol 23: 1373–1379.
[27]
Renner S, Braun-Reichhart C, Blutke A, Herbach N, Emrich D, et al. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820.
[28]
Yamagishi S, Matsui T (2010) Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 3: 101–108. doi: 10.4161/oxim.3.2.11148
[29]
Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, et al. (2004) AGEs activate mesangial TGF-β-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 66: 2137–2147. doi: 10.1111/j.1523-1755.2004.66004.x
[30]
Mason RM, Wahab NA (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14: 1358–1373. doi: 10.1097/01.asn.0000065640.77499.d7
[31]
Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889–9897.
[32]
Kanetsuna Y, Takahashi K, Nagata M, Gannon MA, Breyer MD, et al. (2007) Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol 170: 1473–1484. doi: 10.2353/ajpath.2007.060481
[33]
Cheng H, Wang H, Fan X, Paueksakon P, Harris RC (2012) Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice. Kidney Int 82: 1176–1183. doi: 10.1038/ki.2012.248
[34]
Kosugi T, Heinig M, Nakayama T, Connor T, Yuzawa Y, et al. (2009) Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. Am J Pathol 174: 1221–1229. doi: 10.2353/ajpath.2009.080605
[35]
Mendel DB, Hansen LP, Graves MK, Conley PB, Crabtree GR (1991) HNF-1 alpha and HNF-1 beta (vHNF-1) share dimerization and homeo domains, but not activation domains, and form heterodimers in vitro. Genes Dev 5: 1042–1056. doi: 10.1101/gad.5.6.1042
